(Q40177428)

18 September 2017

title

Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients (English)

1 reference

18 September 2017

10

1 reference

18 September 2017

C Gneiss

1

1 reference

18 September 2017

P Tripp

2

1 reference

18 September 2017

F Reichartseder

3

1 reference

18 September 2017

R Egg

4

1 reference

18 September 2017

R Ehling

5

1 reference

18 September 2017

A Lutterotti

6

1 reference

18 September 2017

M Khalil

7

1 reference

18 September 2017

B Kuenz

8

1 reference

18 September 2017

I Mayringer

9

1 reference

18 September 2017

T Berger

11

1 reference

18 September 2017

F Deisenhammer

12

1 reference

18 September 2017

publication date

1 December 2006

1 reference

Multiple Sclerosis Journal

18 September 2017

published in

1 reference

18 September 2017

volume

12

1 reference

18 September 2017

issue

6

1 reference

18 September 2017

page(s)

731-737

1 reference

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070941

Selecting a disease-modifying agent as platform therapy in the long-term management of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070941

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070941

Neutralising antibodies to interferon beta during the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070941

Biologic impact of interferon antibodies, and complexities in assessing their clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070941

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070941

Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070941

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070941

An Analysis of Neutralization Reaction of Interferon by Antibody: A Proposal on the Expression of Neutralization Titer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070941

Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070941

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070941

The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070941

A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070941

Strategies to treat and prevent the development of neutralizing anti-interferon-β antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070941

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070941

Immunoglobulin Subclasses in Patients with Neutralizing and Nonneutralizing Antibodies Against IFN-β1b

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070941

21 January 2018

Identifiers

DOI

10.1177/1352458506070941

1 reference

18 September 2017

1 reference